31 October 2023
31 October 2023
Sebela Women’s Health has announced that its investigational copper IUD shows a reduction in pain and bleeding in post-hoc analysis.
Roche and Sarepta’s DMD drug failed to meet its primary endpoint in patients with patients with DMD aged 4-7 years.
Patients who received Jemperli in combination with chemotherapy followed by Jemperli alone had better survival than those receiving the placebo.
Rishi Sunak’s speech follows the release of a landmark AI report from the UK government highlighting serious threats posed by the emerging tech.
The long-term safety profile of delgocitinib cream was in line with that recorded in prior data from DELTA 1 and 2 trials.
No drug-linked or treatment-emergent serious adverse events were reported following treatment with brilaroxazine.
The study will assess mezigdomide in combination with either 40mg or 60mg of selinexor plus dexamethasone.
ALX-001 is currently being studied in a Phase Ib safety study and designs for a Phase II ALX-001 proof-of-concept study are underway.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
